To avoid being dependent on decisions by national authorities concerning the setting of prices for medicines or their inclusion in national health insurance schemes, products for which paediatric data is supposed to be submitted but which have received marketing authorisation in all Member States will be granted a 6-month extension of the Supplementary Protection Certificate.
Regula arī paredz uzlabot pieejamo informāciju par zāļu lietošanu, kā arī nosaka, kā sasniegt regulas mērķus, nepakļaujot bērnus nevajadzīgiem klīniskajiem izmēģinājumiem.